Anagenex
Anagenex is a drug discovery company aiming to accelerate the process of bringing new medicines to patients. They address the traditional 25-year timeline by leveraging AI and large-scale data generation. Their platform involves testing billions of custom-synthesized compounds to identify potential modulators for disease-related proteins. The results from these experiments train proprietary neural networks, enabling their generative AI to design millions of new compound experiments. They can then build and test hundreds of millions of these compounds monthly, creating a virtuous cycle of data generation and AI refinement to discover medicines faster.
Anagenex
Anagenex is a drug discovery company aiming to accelerate the process of bringing new medicines to patients. They address the traditional 25-year timeline by leveraging AI and large-scale data generation. Their platform involves testing billions of custom-synthesized compounds to identify potential modulators for disease-related proteins. The results from these experiments train proprietary neural networks, enabling their generative AI to design millions of new compound experiments. They can then build and test hundreds of millions of these compounds monthly, creating a virtuous cycle of data generation and AI refinement to discover medicines faster.
TL;DR
What they do: AI-driven, data-centric platform for small-molecule drug discovery using large-scale synthesized compound testing and generative models
Founded: 2019
Headquarters: Lexington, Massachusetts
Recent financing: Series A announced June 8, 2022 (lead: Catalio Capital Management)
Notable investors: Catalio Capital Management, Lux Capital, Menlo Ventures, Khosla Ventures, Obvious Ventures, Air Street Capital, Expeditions
Company Overview
Problem Domain
Small-molecule drug discovery; identifying modulators for disease-related proteins.
Founded
2019
Industry
Biotechnology
Funding Track Record
30000000
Series A announced June 8, 2022
Investor Signal
“Backed by multiple specialty and venture investors including Catalio Capital Management, Lux Capital, Menlo Ventures, Khosla Ventures, Obvious Ventures, Air Street Capital, Expeditions”